Compare Ascendis Pharma A/S (ASND) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Noble Corporation plc — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Noble Corporation plc trades at $44.15 (market cap $7.10B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NE | |
|---|---|---|
Market Cap | $16.67B | $7.10B |
Sector | Health | Technology |
52-Week High | $277.18 | $54.37 |
52-Week Low | $189.74 | $26.61 |
Enterprise Value | $17.04B | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Noble Corporation (NE) trades at $44.08, up 1.22% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, missing EPS estimates but securing $200 million in new contracts. Revenue and net income are trending lower year-over-year, with a P/E ratio of 47.32 indicating a premium valuation. Recent news highlights multiple law firm investigations into the company.
The outlook is cautious. While a $6.8 billion backlog and consistent dividends provide support, declining profitability, high valuation, and legal scrutiny present significant risks. Analyst consensus is a Hold with a $46.00 price target, suggesting limited near-term upside from current levels amid operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
